
    
      Myval European Study: A retrospective, multicentre, observational study in patients
      presenting with native severe aortic valve stenosis and treated with Myval™ Transcatheter
      Heart Valve System in real-world setting.

      This study shall retrospectively collect the data of minimum 200 consecutive patients treated
      with Myval THV system between 01-June-2019 to 30-June-2020 from approximately 15
      participating sites in Europe.

      Primary Endpoint:

      Primary Combined Safety and Effectiveness Endpoint: [Time frame: 30 days]

      It is the composite of following:

        -  All-cause mortality

        -  All stroke (disabling and non-disabling)

        -  Life-threatening or disabling bleeding

        -  Acute kidney injury (stage 2 or 3)

        -  Major vascular complications

        -  Moderate or severe prosthetic valve regurgitation

        -  Conduction system disturbances resulting in a new permanent pacemaker implantation.

      Secondary endpoints:

        1. All-cause mortality (VARC-2 defined criteria) [Time Frame: Through 30 days]

        2. All stroke (disabling and non-disabling) [Time Frame: Through 30 days]

             -  Disabling stroke: an mRS score of 2 or more at 90 days and an increase in at least
                one mRS category from an individual's pre-stroke baseline

             -  Non-disabling stroke: an mRS score of 2 at 90 days or one that does not result in
                an increase in at least one mRS category from an individual's pre-stroke baseline

           Note: As per VARC-2, the assessment of the mRS should be done at all scheduled visits in
           a trial and at 90 days after the onset of any stroke.

        3. Acute Kidney Injury (AKI) based on the Acute Kidney Injury Network (AKIN) System Stage 3
           (including renal replacement therapy) or Stage 2 [Time Frame: Through 30 days]

        4. Life-threatening or disabling bleeding (VARC-2 criteria) [Time Frame: Through 30 days]

        5. Moderate or severe prosthetic valve regurgitation [Time Frame: Through 30 days]

        6. New permanent pacemaker implantation [Time Frame: Through 30 days] New permanent
           pacemaker implantation rates will be analyzed further based on the patient's history of
           left and/or right bundle branch block.

        7. Conduction disturbances and arrhythmias according to VARC-2 [Time Frame: Through 30
           days]

        8. Device success (VARC-2 criteria) [Time Frame: Pre-discharge]

        9. Early safety at 30 days (VARC-2 criteria) [Time Frame: After 30 days of index procedure]

       10. Clinical efficacy after 30 days (VARC-2 criteria) [Time Frame: After 30 days of index
           procedure]

       11. Time-related valve safety (VARC-2 criteria) [Time Frame: Through 30 days]

       12. Vascular and access related complications (VARC-2 criteria) [Time Frame: Pre-discharge,
           Through 30 days]

       13. Major vascular complications (VARC-2 criteria) [Time Frame: Pre-discharge, Through 30
           days]

       14. Functional improvement from baseline as measured per

           a. NYHA functional classification [Time frame: Baseline, 30 days]

       15. Echocardiographic End Points

             -  Effective orifice area (EOA)

             -  Index effective orifice area (iEOA)

             -  Mean aortic valve gradient

             -  Peak aortic valve gradient

             -  Peak aortic velocity

             -  Transvalvular, paravalvular and total aortic regurgitation

             -  Left ventricular ejection fraction (LVEF)

             -  Valve calcification

             -  Cardiac output and cardiac index [Time frame: Through 30 days]

       16. Patient-prosthesis Mismatch: [Time Frame: Post-procedure, predishcarge, Through 30 days]
           Severity patient-prosthesis-mismatch will be based on following

             -  For subjects with BMI < 30 kg/m2, index effective orifice area (EOAi) 0.85 - 0.65
                cm2 /m2 for moderate and <0.65 cm2 /m2 for severe

             -  For subjects with BMI ≥30 kg/m2, index effective orifice area (EOAi) 0.90 - 0.60
                cm2 /m2 for moderate and <0.60 cm2 /m2 for severe BMI = weight(kg)/(height (m)) 2

       17. Length of index hospital stay. [Time frame: At discharge]

           - Number of days from hospital admission to discharge.

       18. Hospitalization for valve-related symptoms or worsening congestive heart failure (New
           York Heart Association [NYHA] class III or IV) [Time Frame: Through 30 days]

       19. New onset of atrial fibrillation or atrial flutter [Time Frame: Post-procedure,
           Pre-discharge and 30 days]

       20. Endocarditis [Time Frame: Through 30 days]

       21. Major bleeding event [Time Frame: Through 30 days]

       22. Other Endpoints:

             -  Myocardial rupture [Time Frame: During procedure]

             -  Paravalvular leak [Time Frame:Through 30 days]

             -  Degree of over- or under-expansion of Myval [Time Frame: During procedure]

             -  Accuracy of deployment in relation to the annular plane [Time Frame: During
                procedure]

             -  Pacemaker deployment (and the symptoms resulting in it) [Time Frame: Through 30
                days]

             -  Interference with the mitral valve; and [Time Frame: During procedure]

             -  Interference with the LVOT [Time Frame: During procedure]

                  -  If the endpoint data is available through 1 year, it will also be collected
                     and analyzed.

      Clinical efficacy data will be collected only for patients with availability of data after 30
      days follow-up.

      Long term clinical follow up by telephonic interview will be conducted for all patients who
      have completed 30 days safety follow-up, at 1 year, 3 year and 5 years.
    
  